Autologous/syngeneic stem cell transplantation to treat refractory GvHD

Bone Marrow Transplantation

Volumn 34, Issue 11, 2004, Pages 995-998

  Passweg, Jakob R ^a   Orchard, K ^b   Buergi, A ^a   Gratwohl, A ^a   Powles, R ^c   Goldman, J ^b   Apperley, J ^b   Mehta, J ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Autologous; Refractory GvHD; Rescue cell infusion; Syngeneic

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CAMPATH 1G; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTOSTATIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL NUCLEUS; CHIMERA; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SALVAGE THERAPY; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 10044231506     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704658     Document Type: Article

References (15)

1. Gratwohl A, Brand R, Apperley J et al. Graft-versus host disease and outcome in HLA-identical sibling transplantation for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
2. Ferrara J, Teshima T. Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 15-22.
3. Mehta J, Powles R, Singhal S et al. Outcome of autologous rescue after failed engraftment of allogeneic marrow. Bone Marrow Transplant 1996; 17: 213-217.
4. McSweeney P, Niederwieser D, Shizuru J et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
5. Taylor PA, Friedman TM, Korngold R et al. Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood 2002; 99: 4601-4609.
6. Bordignon C, Thomis D, Marktel S et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 1249-1257.
7. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
8. Edinger M, Hoffmann P, Ermann J et al. CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-1150.
9. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821-1828.
10. Weiss L, Slavin S. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999; 23: 1139-1143.
11. Pusic I, Pavletic SZ, Kessinger A et al. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant 2002; 29: 709-710.
12. Nagashima T, Sato F, Chuma T et al. Chronic demyelinating polynewropathy in graft-versus-host disease following allogeneic bone marrow transplantation. Neuropathology 2002; 22 1-8.
13. Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today 1999; 20: 302-306.
14. Wiesmann A, Bader P, Bamberg M et al. Severe acute graft-versus-host disease after T-cell depleted allogeneic stem cell graft from a second donor caused by persisting T-cells from the 1st donor. Bone Marrow Transplant 2003; 32: 511-513.
15. Taranova AG, Georges GE, Yunusov M et al. Breaking tolerance in stable mixed chimeric dogs with low-dose TBI and donor or recipient lymphocyte infusion. Blood 2003; 102: 76a (Abstr. 256).